Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 101, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2021.108183
Keywords
Glioma; Prognosis; Six-transmembrane epithelial antigen of prostate; Immune microenvironment; GSEA; Therapy response
Categories
Ask authors/readers for more resources
This study systematically analyzed the role of the STEAP family in glioma and established risk models based on STEAP gene expression to independently predict the prognosis and treatment response of glioma patients.
Glioma is the most commonly diagnosed primary tumor of central nervous system. Previous studies found that the six-transmembrane epithelial antigen of prostate (STEAP) family can regulate the biological behaviors of several cancers. However, the role of STEAP family in glioma remains unclear. Here, we systematically evaluated the relationship between STEAP family and prognosis of glioma patients in multiple cohorts. The analysis showed that dysregulation of STEAP family may affect cancer-immunity cycle, immune infiltration and phenotypes resulting in an immunosuppressive microenvironment in glioma. To accurately predict the prognosis of glioma patients, gene-based risk models were established based on the expression of STEAP1, 2 and 3. Multivariate and univariate Cox analyses demonstrated that the risk models could independently predict the prognosis of glioma. Finally, chemotherapy and immune therapy responses for high- and low-risk patients were predicted. In conclusion, this study systematically analyzed the role of STEAP family in glioma and established a model for predicting therapy response in patients with glioma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available